A U.S. study has found that less than half of psoriasis patients report frequently engaging in shared decision-making with their...

Guselkumab does not increase cancer risk in psoriasis patients compared to general and psoriasis populations.

Risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17 inhibitors.

There is no increased risk of infections in pediatric psoriasis patients treated with ustekinumab compared to etanercept or methotrexate.

Psoriasis patients are significantly more likely to experience migraines than those without psoriasis.

A new study has evaluated the worldwide prevalence of mental disorders such as depression, anxiety, and suicide in patients with psoriasis.

Patients with comorbid psoriatic arthritis have a slightly decreased treatment response to biologics for psoriasis.

According to a recent study, most psoriasis patients view their comorbid obesity as unrelated to their skin condition.